SG30593G - Use of the agent azelastine in the treatment of psoriasis - Google Patents

Use of the agent azelastine in the treatment of psoriasis

Info

Publication number
SG30593G
SG30593G SG1995905121A SG1995905121A SG30593G SG 30593 G SG30593 G SG 30593G SG 1995905121 A SG1995905121 A SG 1995905121A SG 1995905121 A SG1995905121 A SG 1995905121A SG 30593 G SG30593 G SG 30593G
Authority
SG
Singapore
Prior art keywords
azelastine
treatment
psoriasis
agent
disorders
Prior art date
Application number
SG1995905121A
Other languages
English (en)
Inventor
Juergen Dr Engel
Michael Dr Molliere
Istvan Dr Szelenyi
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of SG30593G publication Critical patent/SG30593G/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02F—DREDGING; SOIL-SHIFTING
    • E02F3/00—Dredgers; Soil-shifting machines
    • E02F3/04—Dredgers; Soil-shifting machines mechanically-driven
    • E02F3/18—Dredgers; Soil-shifting machines mechanically-driven with digging wheels turning round an axis, e.g. bucket-type wheels
    • E02F3/20—Dredgers; Soil-shifting machines mechanically-driven with digging wheels turning round an axis, e.g. bucket-type wheels with tools that only loosen the material, i.e. mill-type wheels
    • E02F3/205—Dredgers; Soil-shifting machines mechanically-driven with digging wheels turning round an axis, e.g. bucket-type wheels with tools that only loosen the material, i.e. mill-type wheels with a pair of digging wheels, e.g. slotting machines
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02F—DREDGING; SOIL-SHIFTING
    • E02F3/00—Dredgers; Soil-shifting machines
    • E02F3/04—Dredgers; Soil-shifting machines mechanically-driven
    • E02F3/88—Dredgers; Soil-shifting machines mechanically-driven with arrangements acting by a sucking or forcing effect, e.g. suction dredgers
    • E02F3/90—Component parts, e.g. arrangement or adaptation of pumps
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02F—DREDGING; SOIL-SHIFTING
    • E02F3/00—Dredgers; Soil-shifting machines
    • E02F3/04—Dredgers; Soil-shifting machines mechanically-driven
    • E02F3/88—Dredgers; Soil-shifting machines mechanically-driven with arrangements acting by a sucking or forcing effect, e.g. suction dredgers
    • E02F3/90—Component parts, e.g. arrangement or adaptation of pumps
    • E02F3/92—Digging elements, e.g. suction heads
    • E02F3/9212—Mechanical digging means, e.g. suction wheels, i.e. wheel with a suction inlet attached behind the wheel

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mining & Mineral Resources (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Structural Engineering (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Civil Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG1995905121A 1989-01-11 1990-01-03 Use of the agent azelastine in the treatment of psoriasis SG30593G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3900607 1989-01-11

Publications (1)

Publication Number Publication Date
SG30593G true SG30593G (en) 1995-09-18

Family

ID=6371863

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1995905121A SG30593G (en) 1989-01-11 1990-01-03 Use of the agent azelastine in the treatment of psoriasis
SG1995905105A SG30591G (en) 1989-01-11 1990-01-03 Use of azelastin and glycerine ethers for the treatment of psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG1995905105A SG30591G (en) 1989-01-11 1990-01-03 Use of azelastin and glycerine ethers for the treatment of psoriasis

Country Status (15)

Country Link
US (1) US5110814A (fr)
EP (2) EP0378086B1 (fr)
JP (1) JP2991733B2 (fr)
AT (2) ATE111735T1 (fr)
AU (1) AU618443B2 (fr)
CA (1) CA2007480C (fr)
DE (3) DE59007531D1 (fr)
DK (2) DK0533213T3 (fr)
EG (1) EG19912A (fr)
ES (2) ES2063841T3 (fr)
HK (2) HK50495A (fr)
IE (1) IE65336B1 (fr)
MC (1) MC2078A1 (fr)
PT (1) PT92821B (fr)
SG (2) SG30593G (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
DE19826517B4 (de) * 1998-06-15 2006-03-23 Baxter Healthcare S.A. Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
DE10028638A1 (de) 2000-06-09 2001-12-20 Schuelke & Mayr Gmbh Lagerstabile Zusammensetzungen von Glycerinmonoalkylethern
CA2543689A1 (fr) * 2003-10-31 2005-05-12 Hexal Ag Preparation pharmaceutique contenant des substances actives et presentant un enrobage
WO2005077963A1 (fr) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes.
DK2486942T3 (en) * 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
CN105307655B (zh) 2013-03-13 2019-05-03 弗拉特利发现实验室有限责任公司 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
US10835584B2 (en) 2016-06-17 2020-11-17 Nuvothera, Inc. Systems for treating dermal inflammatory conditions
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) * 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
JP7498551B2 (ja) * 2019-09-26 2024-06-12 株式会社Adeka 抗炎症剤
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840606A (en) * 1969-12-05 1974-10-08 Oreal Process of producing mono and polyhydroxyl ethers
CH572914A5 (fr) * 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
US4871733A (en) * 1984-04-09 1989-10-03 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs

Also Published As

Publication number Publication date
ATE111735T1 (de) 1994-10-15
HK50495A (en) 1995-04-13
JP2991733B2 (ja) 1999-12-20
ATE113208T1 (de) 1994-11-15
ES2061307T3 (es) 1994-12-01
HK50595A (en) 1995-04-13
CA2007480A1 (fr) 1990-07-17
CA2007480C (fr) 1995-08-15
EP0378086B1 (fr) 1994-10-26
EP0378086A3 (fr) 1991-02-06
PT92821A (pt) 1990-07-31
IE900098L (en) 1990-07-11
DE59007288D1 (de) 1994-10-27
EP0533213B1 (fr) 1994-09-21
JPH02288827A (ja) 1990-11-28
IE65336B1 (en) 1995-10-18
US5110814A (en) 1992-05-05
MC2078A1 (fr) 1991-01-07
PT92821B (pt) 1995-12-29
DK0533213T3 (da) 1994-10-17
ES2063841T3 (es) 1995-01-16
AU4786290A (en) 1990-07-19
DK0378086T3 (da) 1994-12-12
EG19912A (en) 1996-05-31
AU618443B2 (en) 1991-12-19
DE59007531D1 (de) 1994-12-01
SG30591G (en) 1995-09-18
EP0533213A1 (fr) 1993-03-24
DE4000070A1 (de) 1990-07-12
EP0378086A2 (fr) 1990-07-18

Similar Documents

Publication Publication Date Title
EP0378086A3 (fr) Utilisation de l'agent azélastine pour le traitement du psoriasis
GB2188844B (en) Pharmaceutical composition for the treatment of psoriasis
MY103352A (en) Piperazinyl-heterocyclic compounds
ZA804180B (en) Medicaments for the treatment of disorders in lipometabolism and their use
EP0204597A3 (en) Use of alfuzosine in the treatment of urinary affections
IT1224594B (it) Impiego in terapeutica di derivati del 4h-benzo-4,5-cicloepta-1,2-bqti ofene
BR8905555A (pt) Aparelho e processo para suportar corpo humano
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
FI891986A7 (fi) Farmaseuttiset koostumukset psoriasiksen hoitoon
FR2609391B1 (fr) Preparations pharmaceutiques sous forme de suppositoires bioadhesifs
DK0397175T3 (da) Substituerede pyrrolizinforbindelser og deres anvendelse inden for farmacien
NO921223D0 (no) Kombinasjonspreparat med antitrombotisk virkning
IT1252603B (it) 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
DK317285A (da) Farmakologisk virksomme (pyrrol-1-yl)-phenyl-dihydropyridazinoner ogfremgangsmaade til fremstilling heraf
NO922136L (no) Anvendelse av gibberelliner for behandling av prostatitisog psoriasis
FI954138L (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
IT1163107B (it) Composizioni farmaceutiche e loro uso nel trattamento del glaucoma
IL99236A0 (en) Pharmaceutical composition for the topical treatment of psoriasis
IT1147724B (it) Apparecchio di idroterapia in particolare per il trattamento delle algie vertebrali
IT8448370A0 (it) Citrato trisodico utilizzabile nella cura delle malattie artriticoreumatiche
ATE52917T1 (de) Kombinationspraeparat.
EP0407016A3 (en) Use of benzodioxinopyrrole derivatives in the treatment of anxiety
FR2584605B1 (fr) Application du n-(1-allyl-2-pyrrolidinylmethyl) 2-methoxy 4-amino 5-methylsulfamoyl benzamide dans le traitement de la maladie de parkinson
IT1219568B (it) Uso di enalapril nel trattamento terapeutico delle cefalee essenziali